Great bonds make Great Proteins.

Integrated services to take your molecule from gene sequence to potential drug candidate. Across multiple host systems - bacterial, yeast and mammalian.

Quick Certain Secure
Process Development

Process Development

Process development at Premas covers a significant broad spectrum of R&D activities coupled with various input parameters based on in silico analysis, real-world evidence and analytical data. Process development initiates with significant clone development strategies; which then is concomitantly scaled up from shake flasks, to small scale bioreactors (0.5-2.0L) and subsequently into 5L-50L-500L-1100L capacities.

Our upstream process development group develops high cell density E. coli batch, fed-batch and semi-continuous processes for therapeutic recombinant proteins. This group interacts with the strategy and clone development groups from the initiation of the project. This allows for the final objective to clearly evident and visible to the PD group and subsequent downstream and manufacturing groups. COGS, and process simplicity is one of our target hallmarks of working with Premas.

Monoclonal antibodies and mammalian derived proteins, produced from mammalian cell cultures are process developed with similar thoughts. Our approach is flexible, partnership based keeping our clients’ needs. Wave bioreactors (5-25L) and Single Use (1-10L) constitute the first line of process development and scaling up. Gram level yields at the clone /shake flask levels are enhanced with media development, optimizing feed strategies, upstream process development and multi-parametric inputs and controls.

Our downstream process development team has delivered over >650 proteins, of which about 100’s of them have been scale up to > 100L culture volumes. With unit operations scalable to 1000’s of grams of product, harvesting and clarification steps have significant capacities, throughput, and access to multiple options, e.g. high speed continuous centrifuges, concentrations and diafiltrations systems (1000’s of Liters), both cassette and hollow fiber based systems.

Chromatography systems and highly defined process protocols exist at Premas. With the vast experience of over 14 years, Premas has developed unique scale down models (ml to 100’sof L) and processes to rapidly conclude on possible steps, yields and outcomes. (Reference: Application Note: Gene to Phase 1 material in 10 months). Use of multi-modal components and analysis, Premas has been able to deliver some of the significantly challenging products and processes at low COGs.

Further downstream process development is possible at Premas where we develop high protein concentration formulations and lyophilization cycles. Premas has both small and large scale development lyophilizers.

Corona Virus

D-Crypt for Covid 19

Premas specializes in developing recombinant proteins for vaccine development. Such proteins are often “difficult to express proteins” (DTE-Ps). Our innovative D-Crypt platform is optimized for highyield production of DTE-Ps, singularly, or in combination.

Through a partnership with Akers Biosciences, Premas is leveraging DCrypt to develop a multicomponent recombinant protein vaccine against COVID-19.

Contact Us to learn more about our COVID-19 Vaccine Candidate or about our vaccine development services.

Know more